KUALA LUMPUR, Sept 10 -- Aptorum Group Limited (Aptorum Group), a biopharmaceutical company has initiated investigational new drug (IND)-enabling studies for ALS-4, a small drug molecule candidate indicated for treatment of infections.
The infections caused by Staphylococcus aureus (S. aureus), including methicillin-resistant Staphylococcus aureus, are based on a novel anti-virulence approach, according to a statement.
S. aureus is a bacteria which is a leading cause of blood, lung, skin, bone and device-related infections, as well as toxin-related diseases.
It is estimated that patients with S. aureus bacteremia have an average mortality rate of 30 per cent and causes more deaths than AIDS, tuberculosis and viral hepatitis combined.
The ALS-4 candidate has been progressing well and the first series of GLP toxicology studies have been completed through an appointed North American based contract research organisation.
In particular, the ALS-4 candidate did not show any mutagenicity in the in vitro Ames tests. ALS-4 development is on track and the company targets to submit the related IND in the first half of 2020. A hybrid Phase 1 clinical study is currently planned in North America.
More information at http://www.aptorumgroup.com.
-- BERNAMA
No comments:
Post a Comment